Compared side by side

Tirzepatide vs enicepatide: how they differ

Reviewed How we check the libraryPublished by PepVault

The short answer

Both are weekly shots that switch on the GLP-1 and GIP receptors; enicepatide, from Roche, is built to trigger the receptors’ main signal while barely recruiting beta-arrestin, the protein that pulls receptors inside the cell, with the aim of keeping them responsive. Tirzepatide is FDA-approved, as Mounjaro and Zepbound; enicepatide has been in phase 3 since March 2026 and isn’t approved anywhere. Tirzepatide’s 15 mg produced up to 22.5% weight loss at 72 weeks (SURMOUNT-1), and in its 48-week phase 2 obesity trial enicepatide’s top 24 mg dose took off about 22.5% more weight than placebo.

Side by side

ComparedTirzepatideEnicepatide
CategoryMetabolic & GLP-1Metabolic & GLP-1
Also known asMounjaro, Zepbound, LY3298176CT-388, CT388, RO7795068
What it isThe first dual GIP/GLP-1 receptor agonist: it activates two gut-hormone pathways at once, and in a head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks).A weekly GLP-1 and GIP dual agonist from Roche, the same two receptors as tirzepatide, built to keep the receptors responsive by avoiding one of their shut-off signals.
How it worksDual GIP/GLP-1 receptor agonist. Significantly reduces body weight through appetite suppression, slowed gastric emptying, and improved insulin sensitivity. Approved for T2DM and obesity management.Once-weekly peptide that switches on both the GLP-1 and the GIP receptors, tirzepatide's pair, with a twist: it is built to trigger the receptors' main signal while barely recruiting beta-arrestin, the protein that pulls receptors inside the cell. The idea is that receptors stay on the surface and keep responding, so the effect lasts. Its half-life in people is about 5 to 6 days. Developed by Carmot Therapeutics and now Roche, in phase 3 since March 2026.
Commonly reportedVery strong appetite suppression and meals ending early, with nausea or tiredness for a day or two after the injection, mostly after dose increases. FDA-approved for diabetes (Mounjaro) and for weight management and sleep apnea (Zepbound).In trials, GI side effects, mostly mild to moderate, during the step-ups. It is in phase 3 and not approved anywhere.
Studied rangeFDA label: 2.5–15 mg, starting dose 2.5 mg.Research range: 4–24 mg, starting dose 2 mg. Studied in research — not a recommendation.
How oftenWeeklyWeekly
Half-life~5 days (FDA label)~5.5 days (measured in people: mean 123–139 hours after single doses; phase 1, Chakravarthy 2026)
RouteSubQ injectionSubQ injection
Typical runFDA-approved for ongoing use. Titrate slowly upward. Community maintains on minimum effective dose.Used continuously, once weekly, in its trials: 48 weeks in both phase 2 trials, with the dose stepped up over as long as 27 weeks. No trial has tested stopping it.
EvidenceEstablished: clinical trials or FDA-approved use existsModerate: animal studies + some human data
Common side effectsNausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigueNausea, constipation, diarrhea, vomiting

Typical run: Community practice — opinions vary. Not a clinical recommendation.

A smiling man in a grey t-shirt in his living room, holding his phone

Model. Individual results vary.

PepVault for iPhone

Taking tirzepatide or enicepatide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

Tirzepatide

  • Day 1–28 · 2.5 mg Getting your gut acclimated
  • Day 29–56 · 5 mg First therapeutic dose — weight drops
  • Day 57–112 · 7.5 mg Dual agonism in full effect
  • Day 113–168 · 12.5 mg Max titration reached
  • Day 169–504 Weeks 24 to 72: where most people plateau
  • Day 365+ A maintenance medication, not a course

Every card for tirzepatide, with its sources

Enicepatide

  • Day 1–28 · 2 mg Two milligrams, the first step
  • Day 29–112 · 8 mg Through the middle steps
  • Day 85–336 With type 2 diabetes
  • Day 113–336 · 24 mg The top dose tested
  • Day 337+ A long-term medicine, not a course

Every card for enicepatide, with its sources

Questions people ask

How long do tirzepatide and enicepatide last?

The half-life of tirzepatide is ~5 days (FDA label). The half-life of enicepatide is ~5.5 days (measured in people: mean 123–139 hours after single doses; phase 1, Chakravarthy 2026).

How often are tirzepatide and enicepatide taken?

Tirzepatide: weekly. Route: SubQ injection. Enicepatide: weekly. Route: SubQ injection.

How are tirzepatide and enicepatide dosed in research?

The FDA label range for tirzepatide is 2.5–15 mg, with a 2.5 mg starting dose. The research range for enicepatide is 4–24 mg, with a 2 mg starting dose. Studied in research — not a recommendation.

What are the common side effects of tirzepatide and enicepatide?

For tirzepatide, the library lists: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue. For enicepatide: nausea, constipation, diarrhea, vomiting.

Each one in full

Track it in the app

PepVault for iPhone

Taking tirzepatide or enicepatide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo